Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 334

1.

Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study.

Tateishi K, Ko R, Shukuya T, Okuma Y, Watanabe S, Kuyama S, Murase K, Tsukita Y, Ashinuma H, Nakagawa T, Uematsu K, Nakao M, Mori Y, Kaira K, Mouri A, Miyabayashi T, Sakashita H, Matsumoto Y, Tanigawa T, Koizumi T, Morita S, Kobayashi K, Nukiwa T, Takahashi K; North East Japan Study Group.

Oncologist. 2019 Nov 26. pii: theoncologist.2019-0593. doi: 10.1634/theoncologist.2019-0593. [Epub ahead of print]

PMID:
31771990
2.

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.

Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group.

J Clin Oncol. 2019 Nov 4:JCO1901488. doi: 10.1200/JCO.19.01488. [Epub ahead of print]

PMID:
31682542
3.

Correction to: Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib.

Tamura K, Nukiwa T, Gemma A, Yamamoto N, Mizushima M, Ochai K, Ikeda R, Azuma H, Nakanishi Y.

Int J Clin Oncol. 2019 Sep;24(9):1169. doi: 10.1007/s10147-019-01488-w.

4.

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.

Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M.

Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8.

PMID:
30975627
5.

Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib.

Tamura K, Nukiwa T, Gemma A, Yamamoto N, Mizushima M, Ochai K, Ikeda R, Azuma H, Nakanishi Y.

Int J Clin Oncol. 2019 Aug;24(8):917-926. doi: 10.1007/s10147-019-01439-5. Epub 2019 Apr 5. Erratum in: Int J Clin Oncol. 2019 Jun 25;:.

6.

Safety and pharmacokinetics of Alpha-1 MP (Prolastin®-C) in Japanese patients with alpha1-antitrypsin (AAT) deficiency.

Seyama K, Nukiwa T, Sato T, Suzuki M, Konno S, Takahashi K, Nishimura M, Steinmann K, Sorrells S, Chen J, Hayashi KI.

Respir Investig. 2019 Jan;57(1):89-96. doi: 10.1016/j.resinv.2018.09.006. Epub 2018 Nov 8.

PMID:
30416054
7.

Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs.

Watanabe S, Yamaguchi OU, Masumoto AI, Maeno Y, Kawashima Y, Ishimoto O, Sugawara S, Yoshizawa H, Kikuchi T, Nukiwa T, Kobayashi K.

Anticancer Res. 2018 Aug;38(8):4699-4704. doi: 10.21873/anticanres.12776.

PMID:
30061238
8.

Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study.

Ko R, Shukuya T, Okuma Y, Tateishi K, Imai H, Iwasawa S, Miyauchi E, Fujiwara A, Sugiyama T, Azuma K, Muraki K, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Morita S, Kobayashi K, Nukiwa T, Takahashi K; North East Japan Study Group.

Oncologist. 2018 Oct;23(10):1210-1217. doi: 10.1634/theoncologist.2017-0586. Epub 2018 Mar 22.

9.

Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations.

Oizumi S, Sugawara S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Watanabe S, Ito K, Gemma A, Demura Y, Fukumoto S, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Aiba K, Nukiwa T.

ESMO Open. 2018 Feb 23;3(2):e000313. doi: 10.1136/esmoopen-2017-000313. eCollection 2018.

10.

Identification of Secretory Leukoprotease Inhibitor As an Endogenous Negative Regulator in Allergic Effector Cells.

Matsuba S, Yabe-Wada T, Takeda K, Sato T, Suyama M, Takai T, Kikuchi T, Nukiwa T, Nakamura A.

Front Immunol. 2017 Nov 13;8:1538. doi: 10.3389/fimmu.2017.01538. eCollection 2017.

11.

Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.

Morikawa N, Inoue A, Sugawara S, Maemondo M, Harada T, Harada M, Fujita Y, Katoh T, Yokouchi H, Watanabe H, Usui K, Suzuki T, Sakakibara-Konishi J, Nagai H, Kanbe M, Nukiwa T.

Lung Cancer. 2017 Sep;111:38-42. doi: 10.1016/j.lungcan.2017.06.016. Epub 2017 Jul 1.

PMID:
28838395
12.

Sequential Granulocyte-Macrophage Colony-Stimulating Factor Inhalation after Whole-Lung Lavage for Pulmonary Alveolar Proteinosis. A Report of Five Intractable Cases.

Ohkouchi S, Akasaka K, Ichiwata T, Hisata S, Iijima H, Takada T, Tsukada H, Nakayama H, Machiya JI, Irokawa T, Ogawa H, Shibata Y, Ichinose M, Ebina M, Nukiwa T, Kurosawa H, Nakata K, Tazawa R.

Ann Am Thorac Soc. 2017 Aug;14(8):1298-1304. doi: 10.1513/AnnalsATS.201611-892BC.

PMID:
28421817
13.

Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer.

Tode N, Kikuchi T, Sakakibara T, Hirano T, Inoue A, Ohkouchi S, Tamada T, Okazaki T, Koarai A, Sugiura H, Niihori T, Aoki Y, Nakayama K, Matsumoto K, Matsubara Y, Yamamoto M, Watanabe A, Nukiwa T, Ichinose M.

Cancer Sci. 2017 Jun;108(6):1263-1270. doi: 10.1111/cas.13233. Epub 2017 May 11.

14.

Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials.

Azuma A, Taniguchi H, Inoue Y, Kondoh Y, Ogura T, Homma S, Fujimoto T, Sakamoto W, Sugiyama Y, Nukiwa T.

Respirology. 2017 May;22(4):750-757. doi: 10.1111/resp.12960. Epub 2016 Dec 20.

PMID:
27997064
15.

EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method.

Watanabe K, Fukuhara T, Tsukita Y, Morita M, Suzuki A, Tanaka N, Terasaki H, Nukiwa T, Maemondo M.

Can Respir J. 2016;2016:5297329. doi: 10.1155/2016/5297329. Epub 2016 Jul 13.

16.

OX40 ligand newly expressed on bronchiolar progenitors mediates influenza infection and further exacerbates pneumonia.

Hirano T, Kikuchi T, Tode N, Santoso A, Yamada M, Mitsuhashi Y, Komatsu R, Kawabe T, Tanimoto T, Ishii N, Tanaka Y, Nishimura H, Nukiwa T, Watanabe A, Ichinose M.

EMBO Mol Med. 2016 Apr 1;8(4):422-36. doi: 10.15252/emmm.201506154.

17.

Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion.

Watanabe S, Inoue A, Nukiwa T, Kobayashi K.

Anticancer Res. 2015 Dec;35(12):6957-61.

PMID:
26637922
18.

Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.

Taguchi Y, Ebina M, Hashimoto S, Ogura T, Azuma A, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sugiyama Y, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan.

Respir Investig. 2015 Nov;53(6):279-87. doi: 10.1016/j.resinv.2015.06.002. Epub 2015 Oct 23.

PMID:
26521105
19.

Risk factors for acute exacerbation of idiopathic pulmonary fibrosis--Extended analysis of pirfenidone trial in Japan.

Kondoh Y, Taniguchi H, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sugiyama Y, Kudoh S, Nukiwa T.

Respir Investig. 2015 Nov;53(6):271-8. doi: 10.1016/j.resinv.2015.04.005. Epub 2015 Aug 4.

PMID:
26521104
20.

All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis.

Ogura T, Azuma A, Inoue Y, Taniguchi H, Chida K, Bando M, Niimi Y, Kakutani S, Suga M, Sugiyama Y, Kudoh S, Nukiwa T.

Respir Investig. 2015 Sep;53(5):232-41. doi: 10.1016/j.resinv.2015.06.001. Epub 2015 Aug 17.

PMID:
26344613
21.

Syndecan 4 Mediates Nrf2-dependent Expansion of Bronchiolar Progenitors That Protect Against Lung Inflammation.

Santoso A, Kikuchi T, Tode N, Hirano T, Komatsu R, Damayanti T, Motohashi H, Yamamoto M, Kojima T, Uede T, Nukiwa T, Ichinose M.

Mol Ther. 2016 Feb;24(1):41-52. doi: 10.1038/mt.2015.153. Epub 2015 Aug 26.

22.

Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.

Ishimoto O, Sugawara S, Inoue A, Maemondo M, Nukiwa T.

Respir Investig. 2015 Jul;53(4):156-60. doi: 10.1016/j.resinv.2015.02.006. Epub 2015 May 4.

PMID:
26100175
23.

Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.

Inoue A, Sugawara S, Maemondo M, Mori Y, Oizumi S, Harada M, Taima K, Morikawa N, Ishida T, Kinoshita I, Watanabe H, Suzuki T, Nakagawa T, Saito R, Nukiwa T.

Lung Cancer. 2015 Jul;89(1):61-5. doi: 10.1016/j.lungcan.2015.04.012. Epub 2015 May 4.

PMID:
26004087
24.

Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).

Miyauchi E, Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Saijo Y, Yoshizawa H, Hagiwara K, Nukiwa T; North-East Japan Study Group.

Jpn J Clin Oncol. 2015 Jul;45(7):670-6. doi: 10.1093/jjco/hyv054. Epub 2015 Apr 15.

PMID:
25877748
25.

A prospective survey of idiopathic interstitial pneumonias in a web registry in Japan.

Bando M, Sugiyama Y, Azuma A, Ebina M, Taniguchi H, Taguchi Y, Takahashi H, Homma S, Nukiwa T, Kudoh S.

Respir Investig. 2015 Mar;53(2):51-9. doi: 10.1016/j.resinv.2014.11.001. Epub 2014 Dec 4.

PMID:
25745849
26.

Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.

Fukuhara T, Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Saijo Y, Hagiwara K, Morita S, Nukiwa T.

Lung Cancer. 2015 May;88(2):181-6. doi: 10.1016/j.lungcan.2015.02.004. Epub 2015 Feb 9.

27.

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.

Sugawara S, Oizumi S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, Nishitsuji M, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa T; North East Japan Study Group and Tokyo Cooperative Oncology Group.

Ann Oncol. 2015 May;26(5):888-94. doi: 10.1093/annonc/mdv063. Epub 2015 Feb 10.

28.

First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies.

Morikawa N, Minegishi Y, Inoue A, Maemondo M, Kobayashi K, Sugawara S, Harada M, Hagiwara K, Okinaga S, Oizumi S, Nukiwa T, Gemma A; North-East Japan Study Group.

Expert Opin Pharmacother. 2015 Mar;16(4):465-72. doi: 10.1517/14656566.2015.1002396. Epub 2015 Jan 19.

PMID:
25597331
29.

Supramarginal activity in interoceptive attention tasks.

Kashkouli Nejad K, Sugiura M, Nozawa T, Kotozaki Y, Furusawa Y, Nishino K, Nukiwa T, Kawashima R.

Neurosci Lett. 2015 Mar 4;589:42-6. doi: 10.1016/j.neulet.2015.01.031. Epub 2015 Jan 14.

30.

Current status and future perspectives of cooperative study groups for lung cancer in Japan.

Kawano Y, Okamoto I, Fukuda H, Ohe Y, Nakamura S, Nakagawa K, Hotta K, Kiura K, Takiguchi Y, Saka H, Okamoto H, Takayama K, Semba H, Kobayashi K, Kenmotsu H, Tsuboi M, Yamamoto N, Nukiwa T, Nakanishi Y.

Respir Investig. 2014 Nov;52(6):339-47. doi: 10.1016/j.resinv.2014.06.004. Epub 2014 Jul 24. Review.

PMID:
25453377
31.

Current status and study activity of lung cancer in Japan.

Nukiwa T.

Respir Investig. 2014 Nov;52(6):315-6. doi: 10.1016/j.resinv.2014.10.001. Epub 2014 Oct 22. No abstract available.

32.

Synergistic cytotoxicity of afatinib and cetuximab against EGFR T790M involves Rab11-dependent EGFR recycling.

Watanuki Z, Kosai H, Osanai N, Ogama N, Mochizuki M, Tamai K, Yamaguchi K, Satoh K, Fukuhara T, Maemondo M, Ichinose M, Nukiwa T, Tanaka N.

Biochem Biophys Res Commun. 2014 Dec 12;455(3-4):269-76. doi: 10.1016/j.bbrc.2014.11.003. Epub 2014 Nov 11.

PMID:
25446083
33.

Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803.

Inoue A, Sugawara S, Harada M, Kobayashi K, Kozuki T, Kuyama S, Maemondo M, Asahina H, Hisamoto A, Nakagawa T, Hotta K, Nukiwa T.

J Thorac Oncol. 2014 Dec;9(12):1805-9. doi: 10.1097/JTO.0000000000000362.

34.

Mesenchymal stem cells correct inappropriate epithelial-mesenchyme relation in pulmonary fibrosis using stanniocalcin-1.

Ono M, Ohkouchi S, Kanehira M, Tode N, Kobayashi M, Ebina M, Nukiwa T, Irokawa T, Ogawa H, Akaike T, Okada Y, Kurosawa H, Kikuchi T, Ichinose M.

Mol Ther. 2015 Mar;23(3):549-60. doi: 10.1038/mt.2014.217. Epub 2014 Nov 6.

35.

Chronic inflammation, lymphangiogenesis, and effect of an anti-VEGFR therapy in a mouse model and in human patients with aspiration pneumonia.

Nihei M, Okazaki T, Ebihara S, Kobayashi M, Niu K, Gui P, Tamai T, Nukiwa T, Yamaya M, Kikuchi T, Nagatomi R, Ebihara T, Ichinose M.

J Pathol. 2015 Mar;235(4):632-45. doi: 10.1002/path.4473. Epub 2015 Jan 7.

PMID:
25348279
36.

Additional treatment with clarithromycin reduces fever duration in patients with influenza.

Higashi F, Kubo H, Yasuda H, Nukiwa T, Yamaya M.

Respir Investig. 2014 Sep;52(5):302-9. doi: 10.1016/j.resinv.2014.05.001. Epub 2014 Jul 11.

PMID:
25169846
37.

Spinal fMRI of interoceptive attention/awareness in experts and novices.

Kashkouli Nejad K, Sugiura M, Thyreau B, Nozawa T, Kotozaki Y, Furusawa Y, Nishino K, Nukiwa T, Kawashima R.

Neural Plast. 2014;2014:679509. doi: 10.1155/2014/679509. Epub 2014 Jun 17.

38.

Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia - short term evaluation of safety and tolerability.

Kamio K, Azuma A, Ohta K, Sugiyama Y, Nukiwa T, Kudoh S, Mizushima T.

BMC Pulm Med. 2014 May 17;14:86. doi: 10.1186/1471-2466-14-86.

39.

Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.

Kawashima Y, Inoue A, Sugawara S, Oizumi S, Maemondo M, Okudera K, Suzuki T, Usui K, Harada M, Morikawa N, Hasegawa Y, Saito R, Ishimoto O, Sakakibara T, Asahina H, Nukiwa T.

Respir Investig. 2014 May;52(3):190-4. doi: 10.1016/j.resinv.2013.12.005. Epub 2014 Jan 28.

PMID:
24853020
40.

Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.

Maemondo M, Inoue A, Sugawara S, Harada T, Minegishi Y, Usui K, Miwa K, Morikawa N, Kambe M, Ube K, Watanabe K, Ishimoto O, Sakakibara T, Gemma A, Nukiwa T.

Oncologist. 2014 Apr;19(4):352-3. doi: 10.1634/theoncologist.2013-0411. Epub 2014 Mar 28.

41.

The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia.

Nakashima R, Imura Y, Hosono Y, Seto M, Murakami A, Watanabe K, Handa T, Mishima M, Hirakata M, Takeuchi T, Fujio K, Yamamoto K, Kohsaka H, Takasaki Y, Enomoto N, Suda T, Chida K, Hisata S, Nukiwa T, Mimori T.

PLoS One. 2014 Jan 14;9(1):e85062. doi: 10.1371/journal.pone.0085062. eCollection 2014.

42.

Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer.

Kobayashi M, Sakakibara T, Inoue A, Fukuhara T, Sasano H, Ichinose M, Nukiwa T.

Respir Investig. 2014 Jan;52(1):49-56. doi: 10.1016/j.resinv.2013.06.003. Epub 2013 Aug 1.

PMID:
24388371
43.

Two years of Respiratory Investigation: articles published and upcoming bimonthly publication.

Nukiwa T.

Respir Investig. 2014 Jan;52(1):1-2. doi: 10.1016/j.resinv.2013.12.001. Epub 2013 Dec 22. No abstract available.

44.

A Novel Missense Mutation of DKC1 In Dyskeratosis Congenita With Pulmonary Fibrosis.

Hisata S, Sakaguchi H, Kanegane H, Hidaka T, Shiihara J, Ichinose M, Kojima S, Nukiwa T, Ebina M.

Sarcoidosis Vasc Diffuse Lung Dis. 2013 Nov 25;30(3):221-5.

PMID:
24284296
45.

Secretory leukocyte protease inhibitor modulates urethane-induced lung carcinogenesis.

Jan Treda C, Fukuhara T, Suzuki T, Nakamura A, Zaini J, Kikuchi T, Ebina M, Nukiwa T.

Carcinogenesis. 2014 Apr;35(4):896-904. doi: 10.1093/carcin/bgt382. Epub 2013 Nov 26.

PMID:
24282288
46.

A change in the number of CCSP(pos)/SPC(pos) cells in mouse lung during development, growth, and repair.

Sun R, Zhou Q, Ye X, Takahata T, Ishiguro A, Kijima H, Nukiwa T, Saijo Y.

Respir Investig. 2013 Dec;51(4):229-40. doi: 10.1016/j.resinv.2013.04.006. Epub 2013 Jun 4.

PMID:
24238231
47.

Transcription repressor Bach2 is required for pulmonary surfactant homeostasis and alveolar macrophage function.

Nakamura A, Ebina-Shibuya R, Itoh-Nakadai A, Muto A, Shima H, Saigusa D, Aoki J, Ebina M, Nukiwa T, Igarashi K.

J Exp Med. 2013 Oct 21;210(11):2191-204. doi: 10.1084/jem.20130028. Epub 2013 Oct 14.

48.

Flagellin/TLR5 signaling potentiates airway serous secretion from swine tracheal submucosal glands.

Muramatsu S, Tamada T, Nara M, Murakami K, Kikuchi T, Kanehira M, Maruyama Y, Ebina M, Nukiwa T, Ichinose M.

Am J Physiol Lung Cell Mol Physiol. 2013 Dec;305(11):L819-30. doi: 10.1152/ajplung.00053.2013. Epub 2013 Oct 4.

49.

Mycobacterium avium genotype is associated with the therapeutic response to lung infection.

Kikuchi T, Kobashi Y, Hirano T, Tode N, Santoso A, Tamada T, Fujimura S, Mitsuhashi Y, Honda Y, Nukiwa T, Kaku M, Watanabe A, Ichinose M.

Clin Microbiol Infect. 2014 Mar;20(3):256-62. doi: 10.1111/1469-0691.12285. Epub 2013 Jul 5.

50.

Deterioration in regional health status after the acute phase of a great disaster: respiratory physicians' experiences of the Great East Japan Earthquake.

Ohkouchi S, Shibuya R, Yanai M, Kikuchi Y, Ichinose M, Nukiwa T.

Respir Investig. 2013 Jun;51(2):50-5. doi: 10.1016/j.resinv.2012.12.003. Epub 2013 Mar 13.

Supplemental Content

Loading ...
Support Center